linjc16/ctgov huggingface dataset:
Slit Lamp and Digital Camera Attachment

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to compare the ease of use and performance of the SL-D301 with the DC-4 with other existing slit lamps imaging systems (SL-3G) from Topcon.

Detailed Description
-----------------
The objective of the study is to compare the ease of use and performance of the SL-D301 with the DC-4 with other existing slit lamps imaging systems (SL-3G) from Topcon and ascertain that the changes and new features incorporated do not interfere with the normal use and application of the device.

Official Title
-----------------
Slit Lamp Model SL-D-301 and DC-4 Digital Camera Attachment

Conditions
-----------------
Any Willing and Able Person for Ocular Imaging

Intervention / Treatment
-----------------
* Device: SL-D301
* Device: DC-4
* Device: SL-3G


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any willing subject Exclusion Criteria: Subjects unwilling to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Any Willing and Able Person for Ocular Imaging<br>Any Willing and Able Person for Ocular Imaging | Device: SL-D301<br>* Slit Lamp<br>Device: DC-4<br>* Digital Camera Attachment<br>Device: SL-3G<br>* Slit Lamp<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Instrument and Device Evaluation |  | 1 Hour |
Diet in the Management of Acromegaly

Study Overview
=================
Brief Summary
-----------------
Impact of low carbohydrate and low gluten diet on acromegaly progression, symptoms, complications, and treatment outcomes.

Official Title
-----------------
Impact of Low Carbohydrate and Low Gluten Diet on Acromegaly Progression, Symptoms, Complications, and Treatment Outcomes

Conditions
-----------------
Acromegaly

Intervention / Treatment
-----------------
* Other: Diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of acromegaly. Exclusion Criteria: Diet restrictions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Carbohydrate<br>Counseling, education, and implementation of low carbohydrate diet. | Other: Diet<br>* Macronutrient diet changes.<br>|
| Active Comparator: Low gluten<br>Counseling, education, and implementation of low gluten diet. | Other: Diet<br>* Macronutrient diet changes.<br>|
| No Intervention: Standard<br>No change/intervention in diet. Continuation of standard diet. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in insulin-like growth factor 1 (IGF-1). | Change in IGF-1 will be assessed from baseline (pre-intervention) to end of follow up. | 8 weeks | 
| Change in growth hormone level (GH). | Change in GH level will be assessed from baseline (pre-intervention) to end of follow up. | 8 weeks | 
| Change in acromegaly related symptoms. | Change in acromegaly related symptoms will be assessed from baseline (pre-intervention) to end of follow up using Acromegaly Quality of Life Questionnaire (AcroQoL). | 8 weeks |
Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of ONO-5129 in patients with type 2 diabetes mellitus.

Official Title
-----------------
Phase II Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: ONO-5129


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fasting Blood Glucose 126-250mg/dL HbA1c 6.5-11% Exclusion Criteria: Previous treatment with antidiabetic agents equal to or less than 2-3 months prior to randomization History of myocardial infarction, coronary artery surgery Other eligibility criteria as specified in the study protocol

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ONO-5129|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fasting Blood Glucose at week 8 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Other glycemic control parameters (e.g., HbA1c, glycoalbumin) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ONO-5129, type 2 diabetes mellitus
The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study

Study Overview
=================
Brief Summary
-----------------
This study will investigate the usefulness of an optical probe in the differentiation of thyroid cancer from normal thyroid tissue in a thyroidectomy specimen.

Detailed Description
-----------------
The optical real-time readings will be compared to the histological analysis from the same area. Subjects undergoing thyroid surgery for thyroid disease including thyroid nodules, thyroid cancer and thyroid goiter with nodules will be eligible to participate. After the removal of the thyroid gland, optical readings will be taken from the ex vivo thyroid gland and these same areas will then be analyzed in the usual standard fashion. The reading will then be correlated with the histological results. In addition, if lymph nodes are removed as part of the surgery they will also be tested prior to histological standard processing. All specimens and data will be de-identified.

Official Title
-----------------
The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study

Conditions
-----------------
Thyroid Nodule, Thyroid Neoplasms, Thyroid Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects undergoing thyroid surgery for thyroid nodules, thyroid cancer, and thyroid goiter with nodules. Exclusion Criteria: Subjects whose thyroid specimens have been put in formalin
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess optical probe for the differentiation of thyroid cancer from normal thyroid tissue and benign thyroid nodules | The objective is to assess a device called an optical probe for the differentiation of thyroid cancer from normal thyroid tissue, benign thyroid nodules or parathyroid glands, and the detection of thyroid cancer within lymph nodes using a hand-held spectroscope, compare the spectra from benign and malignant thyroid nodules and use this to discriminate benign from malignant nodules based on final histopathology or cytology as the gold standard. | two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thyroid Neoplasms, Optical Devices, Spectrum Analysis, Thyroid diseases
Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle

Study Overview
=================
Brief Summary
-----------------
About 10-15% of all couples attempting to conceive will not become pregnant within one year. Among those, the majority will have ovulatory dysfunction, mild male infertility or unexplained infertility. The traditional first line therapy for those couples is ovulation induction or superovulation using clomiphene citrate. Probably due to anti-estrogenic effects of this agent will, some patients will have a thin endometrium as measured by sonography at the time of ovulation. This phenomenon may be associated with a lower chance to conceive. Tamoxifen is a similar molecule that has been used to clomiphene citrate that has been shown to be equally effective to clomiphene in ovulation induction. Preliminary observations showed that tamoxifen does not cause a negative effect on the endometrium as compared with clomiphene, and may increase the chance to conceive in those patients who have a thin endometrium under clomiphene.

Official Title
-----------------
Prospective Randomized Study of Ovulation Induction Using Either Tamoxifen or Clomiphene Citrate for Women Who Had Thin Endometrium During Previous Treatment With Clomiphene Citrate

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: tamoxifen
* Drug: clomiphene citrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary or secondary infertility due to: Ovulatory dysfunction Mild male infertility Unexplained infertility Endometrium < 6 mm at time of hCG during previous treatment with clomiphene citrate Age 18-35 Exclusion Criteria: Serious adverse effects under clomiphene citrate or known sensitivity to either tamoxifen or clomiphene citrate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: tamoxifen|nan|
|Drug: clomiphene citrate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy rate |  |  | 
| delivery rate |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endometrium thickness |  |  | 
| percentage of ovulation |  |  | 
| number of follicles |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infertility, ovulation dysfunction, endometrium, tamoxifen, clomiphene citrate
Pregnancy and Growth of Adolescent Mothers and Their Child

Study Overview
=================
Brief Summary
-----------------
This study intends to observe the epidemiology of pregnancy and growth of adolescent mothers and their child in their first year on the development and growth ambulatory at Brasilia University Hospital (HUB). The study hypothesis is that adolescent growth is disturbed by a pregnancy in this age. Another hypothesis is that their child's growth and development could be obstructed.

Official Title
-----------------
Pregnancy and Growth of Adolescent Mothers and Their Child

Conditions
-----------------
Adolescent, Pregnancy, Development

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: in the HUB ambulatory of growth and development pediatric center Exclusion Criteria: mothers who are more than 19 years old

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Technical Development of Multi-Parametric Renocerebral MRI

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and functional MRI methods along with a battery of cognitive tests.

Official Title
-----------------
Technical Development of Multi-Parametric Renocerebral MRI

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Other: MRI
* Other: MRI
* Other: MRI
* Other: Group 4


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: English-speaking as primary language No hearing loss or uncorrected vision Exclusion Criteria: Lacking capacity to consent Having known history of cardiovascular diseases (e.g., clinical stroke) Having acute and chronic obstructive pulmonary disease Having known history of renal diseases (e.g., acute kidney injury) Having known history of cognitive disorder or psychiatric illness Having known history of chemical dependence (e.g., alcohol and narcotics) Being treated with stimulant medications, anticonvulsants, antihypertensives or ß-adrenergic blockers

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>normal 21-35 years old participants | Other: MRI<br>* Perform MRI studies<br>|
| Group 2<br>normal 36-50 years old participants | Other: MRI<br>* Perform MRI studies<br>|
| Group 3<br>normal 51-65 years old participants | Other: MRI<br>* Perform MRI studies<br>|
| Group 4<br>normal 66- 80 years old participants | Other: Group 4<br>* Perform MRI studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRI measured perfusion for each group | MRI measurements will be summarized for each group by using mean and standard deviation or standard error. | Baseline | 
| MRI measured vascular reactivity for each group | MRI measurements will be summarized for each group by using mean and standard deviation or standard error. | Baseline | 
| Cognitive performance for each group | The total cognitive performance scores will be summarized for each group by using mean and standard deviation or standard error. | Baseline |
The Optimal Effect Site Concentration of Propofol for Conscious Sedation in Elderly Male Patients Undergoing Urologic Surgery Under Spinal Anesthesia With or Without Intrathecal Fentanyl

Study Overview
=================
Brief Summary
-----------------
Since intrathecal fentanyl is known to sedation effect, intrathecal fentanyl will result in lowering propofol requirement for conscious sedation under spinal anesthesia.

Official Title
-----------------
The Optimal Effect Site Concentration of Propofol for Conscious Sedation in Elderly Male Patients Undergoing Urologic Surgery Under Spinal Anesthesia With or Without Intrathecal Fentanyl

Conditions
-----------------
Conscious Sedation Under Spinal Anesthesia

Intervention / Treatment
-----------------
* Drug: propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elderly male patients undergoing urologic surgery under spinal anesthesia Exclusion Criteria: patients with any co-morbidity

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: fentanyl<br> | Drug: propofol<br>* 1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)<br>* Other names: Pofol®;|
| Placebo Comparator: saline<br> | Drug: propofol<br>* 1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)<br>* Other names: Pofol®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral state index | every 1 minute(up to 10-minute) after getting effect site concentration of propofol | 1 minute |
Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy

Study Overview
=================
Brief Summary
-----------------
Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World Health Organization and the National Hansen's Disease Program consider clofazamine to be standard therapy for treatment of multibacillary leprosy. In recent years, the availability of the drug has become limited and is currently available only under a research protocol and is considered investigational. Use of Clofazamine in patients presenting with lepromatous leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other therapies. This drug will be used prospectively for patients who require treatment of leprosy as deemed appropriate by a Kaiser Permanente Southern California physician.

Detailed Description
-----------------
Treatment protocol objective is to treat patients with clofazamine who meet inclusion criteria stated above.

Official Title
-----------------
Clofazamine in the Long Term Treatment of Leprosy, Phase III

Conditions
-----------------
Leprosy

Intervention / Treatment
-----------------
* Drug: clofazamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Known or suspected leprosy confirmed by skin biopsy and/or slit skin smears. Multibacillary leprosy (lepromatous leprosy or borderline-lepromatous). Paucibacillary leprosy (borderline, borderline tuberculoid, or indeterminate) if there is involvement of the cranial nerves or active acute neuritis. Known or suspected ENL(erythema nodosum leprosum) (a specific immune reaction with painful skin nodules and fever) Known or suspected dapsone-resistant leprosy or relapsed leprosy. Intolerance of other antileprosy antibiotic (where clofazamine is substituted as apart of multidrug regimen) Exclusion Criteria: Uncomplicated paucibacillary leprosy which would otherwise be treated with dapsone and rifampin only. Known prior intolerance of Clofazamine Any minor (even with parental consent) Any fertile woman who is pregnant a specific immune reaction with painful skin rash and fever)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: clofazamine|clofazamine 50mg po qday (duration varies according to physician)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multibacillary leprosy, leprosy, clofazamine
Determination of the Independent Effects of Beetroot Juice Components, Dietary Nitrate and Antioxidants, on Exercise Tolerance and Health Benefits in Individuals With Obesity

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effects of acute beetroot juice supplementation on exercise performance and cardiometabolic health in obese individuals with secondary cardiometabolic complications. Additionally, we will determine if the ergogenic health benefits of beetroot juice is due to the nitric oxide compound within the product, the antioxidant compound within the product, or a combination of the two compounds.

Official Title
-----------------
Determination of the Independent Effects of Beetroot Juice Components, Dietary Nitrate and Antioxidants, on Exercise Tolerance and Health Benefits in Individuals With Obesity

Conditions
-----------------
Metabolic Disease, Obesity, Exercise

Intervention / Treatment
-----------------
* Dietary Supplement: Sodium Nitrate
* Dietary Supplement: Beetroot Juice no Nitrate
* Dietary Supplement: Beetroot Juice


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI ≥ 30 kg/m2 Able to perform exercise testing on a cycle ergometer Exclusion Criteria: Currently taking medications know to affect cardiovascular or respiratory function Currently supplementing with an antioxidant compound Current smoker Currently taking antibiotics Not willing to abstain from mouthwash use Currently participating in regular physical activity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Beetroot Juice<br> | Dietary Supplement: Beetroot Juice<br>* 70ml Concentrated Beetroot Juice<br>|
| Active Comparator: Beetroot Juice no Nitrate<br> | Dietary Supplement: Beetroot Juice no Nitrate<br>* 70ml Concentrated Beetroot Juice with nitrate removed<br>|
| Active Comparator: Sodium Nitrate<br> | Dietary Supplement: Sodium Nitrate<br>* 70ml sodium nitrate, matched for nitrate concentration in Beetroot Juice arm<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Exhaustion |  | A Time to Exhaustion Test will be conducted on each participant a total of four times throughout their participation in the study. This will take place approximately 2.5 hours post ingestion of the dietary supplement they are randomized to at each visit. |